Blood Pressure Clinical Trial
— LBPOfficial title:
Growth of Lettuce With Different Content of Inorganic Nitrate as a Feeding Strategy for Placebo-controlled Nutritional Interventions to Test the Effects of Inorganic Nitrate on Human Health
Verified date | May 2016 |
Source | Newcastle University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Ethics Committee |
Study type | Interventional |
Leafy vegetables are a natural source of dietary nitrate, which may reduce systolic blood
pressure (BP). However, the evidence has been obtained from studies using nitrate solutions
(i.e., potassium or sodium nitrate) or beetroot juice supplementation which have a suitable
placebo for the design of double-blind clinical trials. However, the design of food-based
nutritional interventions is complicated by the fact that an appropriate placebo treatment
is not available and, therefore, it is not possible to meet the criteria for proper
double-blind randomised placebo-controlled intervention trials. In addition, the biological
effects of processed products such as beetroot juice or solutions with a pharmacological
grade may be different from that of fresh vegetables, e.g. due to conversion of nitrate to
nitrite in the mouth during chewing.
Objectives: to investigate whether two sets of lettuce specifically grown with different
nitrate content but otherwise similar composition show different effects on nitrate uptake
and bioavailability in humans. Additionally, the investigators also aim to design human
intervention studies to investigate the effect of intake of lettuce with different nitrate
content on vascular health.
These objectives will be tested by growing lettuce with different fertiliser compositions
resulting in high and low nitrate content and then investigating the bioavailability and
short-term effect on BP in healthy young volunteers in a double-blind cross-over design.
Eligible subjects will consume one meal each of either low or high nitrate lettuce. Urine,
blood and saliva samples will be collected at baseline, for 6 hours after the ingestion and
then again after 24hr. Blood Pressure BP will be measured continuously for 24 hours starting
at baseline. The volunteers will repeat the intervention with the second treatment.
Status | Completed |
Enrollment | 20 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion criteria: The investigators aim to recruit 20 healthy young volunteers, non-smoking, male and female aged 18-35 years with a body mass index (BMI) in the range of 20 to 25 kg/m2. Exclusion criteria (reason for exclusion): - Current participation in other clinical investigations. - Mouthwash users. - Vegetarianism (likely to have very high nitrate intake) - Dislike to lettuce consumption or inability to comply with the study diet (lack of compliance) - Use of antihypertensive or cholesterol lowering medication. - History of any major illness such as cancer; or cholesterol lowering medication; history of cardiovascular or peripheral vascular disease; - History of any major illness such as cancer; a psychiatric illness; recent history of asthma, renal, liver or gastrointestinal disease. - Use of antibiotics within previous 2 months; current or recent (within previous 6 months) significant weight loss or gain (>6% of body weight); --woman who were pregnant, lactating or wishing to become pregnant during the study. - Previous diagnosis of type 1 or type-2 diabetes treated with insulin (modification of regulation of intermediate metabolism). - Major surgical operations interfering with the study outcomes (systemic effects on study outcomes). - Alcohol intake >21 units/week for men and >14 units/week women - Non English speakers or volunteers requiring translators or interpreters (since these services are not available for this study). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United Kingdom | School of Agriculture, Food and Rural Development | Newcastle upon Tyne | England |
Lead Sponsor | Collaborator |
---|---|
Newcastle University |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in 24-hour Ambulatory Blood Pressure (AMBP) | Change in Systolic and Diastolic Blood Pressure at baseline and every 30 minutes at day time and every hour at night time for 24 hours. | Baseline and 24 hours | No |
Secondary | Change in bio-availability of nitrate and nitrite in plasma | Change in plasma nitrate and nitrite at baseline, 3 hours, 6 hours and 24 hours from intervention. | 24 hours | No |
Secondary | Change in Cyclic Guanosine Monophosphate (cGMP) in plasma samples | Change in Cyclic Guanosine Monophosphate (cGMP) in plasma samples at baseline, 3 hours, 6 hours and 24 hours from intervention. | 24 hours | No |
Secondary | Change in bio-availability of nitrate and nitrite in urine samples | Change in urinary nitrate and nitrite at baseline, 0-3, 3-6, 6-12 and 12-24 hours from intervention. | 24 hours | No |
Secondary | Change in bio-availability of nitrate and nitrite in saliva samples | Change in salivary nitrate and nitrite at baseline, 0, 1, 2, 3, 4, 5, 6, 9, 12 and 24 hours from intervention. | 24 hours | No |
Secondary | Change in Antioxidant capacity of Ferric Reducing Antioxidant Power (FRAP) and Trolox Equivalent Antioxidant Capacity (TEAC) in plasma samples. | Change in Antioxidant capacity of Ferric Reducing Antioxidant Power (FRAP) and Trolox Equivalent Antioxidant Capacity (TEAC) in plasma samples at baseline, 3 hours, 6 hours and 24 hours from intervention. | 24 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT05997303 -
Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT03918486 -
Caretaker vs. Routine Blood Pressure Sphygmomanometer
|
||
Completed |
NCT03410342 -
The Effects of Types of Fruits and Vegetables on Vascular Function
|
N/A | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT04087070 -
Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
|
||
Completed |
NCT03294928 -
Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers
|
N/A | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03997461 -
Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device
|
N/A | |
Completed |
NCT03290716 -
Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China
|
N/A | |
Recruiting |
NCT05196048 -
Blood Pressure Sensor of Watch-type Device With ECG Technology
|
||
Recruiting |
NCT06460233 -
Blood Pressure Changes After Bariatric Surgery
|
||
Terminated |
NCT03325933 -
Resistance Training and Cardiometabolic Health
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Completed |
NCT02924454 -
Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.
|
Phase 4 | |
Completed |
NCT02451059 -
Reducing Socioeconomic Disparities in Health at Pediatric Visits
|
N/A | |
Active, not recruiting |
NCT02670967 -
Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials
|
N/A | |
Completed |
NCT02239744 -
Intervention Study on the Health Impact of Air Filters in Chinese Adults
|
N/A | |
Completed |
NCT02271633 -
Nitrate Supplementation; Source
|
Phase 4 |